Search
Research
Role of antenatal maternal dietNutrition is a modifiable lifestyle factor that may play a role in allergic disease prevention. This article summarizes current evidence on the antenatal diet as a consideration for strategies to prevent child food allergy. As eczema in early infancy substantially increases the risk of food allergy development, the effects of maternal dietary intakes during pregnancy on infant eczema outcomes will also be discussed.
Research
Two-year post-treatment outcomes following peanut oral immunotherapy in the Probiotic and Peanut Oral Immunotherapy-003 Long-Term (PPOIT-003LT) studyFew studies have examined long-term outcomes following oral immunotherapy; none have examined long-term risks and benefits associated with distinct clinical outcomes (desensitization, remission).
Research
T-cell activation genes differentially expressed at birth in CD4+ T-cells from children who develop IgE food allergyTo show underlying mechanisms, we examined differences in T-cell gene expression in samples at birth and at 1 year in children with and without IgE allergy.
Research
The relationship between maternal folate status in pregnancy, cord blood folate levels, and allergic outcomes in early childhoodThis study examined whether maternal and/or fetal folate status in pregnancy is associated with infant allergic outcomes.
Research
Gene polymorphisms, breast-feeding, and development of food sensitization in early childhoodThe effect of breast-feeding on the development of allergic disease is uncertain
Research
Does genetic regulation of IgE begin in utero?Elucidation of early life factors is critical to understand the development of allergic diseases, especially those manifesting in early life such as food allerg
Research
Allergen Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 YearsRemission is the desired outcome following OIT as it allows individuals to discontinue treatment and eat the allergen freely. Early initiation of OIT in infants and toddlers has been embraced as an approach to increase the likelihood of remission. However, there is no high-quality evidence supporting younger age as an independent factor driving remission; available studies are limited by small samples of younger subjects and lack of adjustment for confounding covariates, particularly peanut-specific IgE (sIgE) levels which is closely cor
Research
A newborn's perspective on immune responses to foodIn this review, we will highlight infants' immune responses to food, emphasizing the unique aspects of early-life immunity and the critical role of breast milk as a food dedicated to infants. Infants are susceptible to inflammatory responses rather than immune tolerance at the mucosal and skin barriers, necessitating strategies to promote oral tolerance that consider this susceptibility.
Research
Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trialOral immunotherapy is effective at inducing desensitisation to allergens and induces sustained unresponsiveness (ie, clinical remission) in a subset of patients, but causes frequent reactions. We aimed to investigate whether addition of a probiotic adjuvant improved the efficacy or safety of peanut oral immunotherapy.
Research
Identifying gene network patterns and associated cellular immune responses in children with or without nut allergyAlthough evidence suggests that the immune system plays a key role in the pathophysiology of nut allergy, the precise immunological mechanisms of nut allergy have not been systematically investigated. The aim of the present study was to identify gene network patterns and associated cellular immune responses in children with or without nut allergy.